Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer-Reference-Cited by-同舟云学术

Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer

Published:2023-05-17 Issue:4 Volume:27 Page:513-523
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Nagakubo Yuki,Hirotsu Yosuke^ORCID,Amemiya Kenji,Mochizuki Hitoshi,Tsutsui Toshiharu,Kakizaki Yumiko,Miyashita Yoshihiro,Higuchi Rumi,Nakagomi Takahiro,Goto Taichiro,Oyama Toshio,Omata Masao

Funder

Japan Society for the Promotion of Science London

Uehara Memorial Foundation

Takeda Medical Research Foundation

Kato Memorial Bioscience Foundation

Yasuda Memorial Medical Foundation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40291-023-00653-2.pdf

Reference25 articles.

1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44. https://doi.org/10.1016/j.ccm.2011.09.001.

2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. https://doi.org/10.4065/83.5.584.

3. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2017;378(2):113–25. https://doi.org/10.1056/NEJMoa1713137.

4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8. https://doi.org/10.1016/S1470-2045(09)70364-X.

5. Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71. https://doi.org/10.1056/NEJMoa1406766.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test;JTO Clinical and Research Reports;2024-06

2. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer;Scientific Reports;2024-05-30

3. Molecular Behavior of α-Synuclein Is Associated with Membrane Transport, Lipid Metabolism, and Ubiquitin–Proteasome Pathways in Lewy Body Disease;International Journal of Molecular Sciences;2024-02-26

4. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions;Scientific Reports;2024-01-18

5. Influence of formalin fixation duration on RNA quality and quantity from formalin‐fixed paraffin‐embedded hepatocellular carcinoma tissues;Pathology International;2023-11-07